Proactive Investors - Run By Investors For Investors

Destiny Pharma PLC welcomes government lead on antibiotics

Neil Clark, chief executive of Destiny Pharma plc (LON:DEST), spoke to Proactive's Andrew Scott following the release last week of a new 5 year action plan by the UK government to tackle the problem of antibiotic resistance.

Clark says the recent awarding of up to £1.6mln to them of new grant funding is validation of the company’s strategy.

He also talks through positive results they've announced from a second phase 1 clinical study of its XF-73 nasal gel.

Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full DEST profile View Profile

Destiny Pharma plc Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use